New hope for rare blood disorder: testing a gentler chemo combo
NCT ID NCT07187193
Summary
This study is testing whether a combination of two existing drugs—a low-dose chemotherapy (cytarabine) and thalidomide—can effectively control Langerhans cell histiocytosis (LCH) in adults who haven't had treatment before. It aims to see if this regimen can keep the disease in check and improve survival with fewer side effects. The trial will enroll about 50 adults at multiple centers in China.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LANGERHANS CELL HISTIOCYTOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.